← Eichor
Condition: Her2 Gene Mutation Synced from ClinicalTrials.gov · July 28, 2026

Recruiting studies: Her2 Gene Mutation

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors
Phase 1 · 40 location(s) · TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · NCT06625775A Study of a Selective ERBB2 Inhibitor (CGT4255), in Patients With Advanced Solid Tumors
Phase 1 · 6 location(s) · Cogent Biosciences, Inc. · NCT07361562Neoadjuvant Camrelizumab and Fluzoparib and Nab-paclitaxel in Early Breast Cancer With HRR Gene Mutation
Phase 2 · 1 location(s) · Ying Lin · NCT05761470Post-op T-DM1 in HER-2+ Salivary Gland Carcinomas
Phase 2 · 13 location(s) · Dana-Farber Cancer Institute · NCT04620187A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer
Phase 3 · 338 location(s) · Eli Lilly and Company · NCT07174336PRE-I-SPY Phase I/Ib Oncology Platform Program
Phase 1 · 7 location(s) · QuantumLeap Healthcare Collaborative · NCT05868226A Study of Mutant Selective-Inhibitor (CGT6297), in Patients With Advanced Solid Tumors
Phase 1 · 4 location(s) · Cogent Biosciences, Inc. · NCT07383506First-in-Human Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, as a Single Agent in Patients With Advanced Solid Tu
Phase 1 · 37 location(s) · Relay Therapeutics, Inc. · NCT05216432Elacestrant in Patients With ER+ HER2- ESR1-mutated Locally Advanced or Metastatic Breast Cancer
Phase N/A · 3 location(s) · iOMEDICO AG · NCT07563595Neratinib and Fam-Trastuzumab Deruxtecan in Advanced Gastro-esophageal Cancer Patients
Phase 1 · 3 location(s) · Fox Chase Cancer Center · NCT05274048HEAT Trial (HER2 Antibody Therapy With Lutetium-177)
EARLY_Phase 1 · 5 location(s) · Radiopharm Theranostics, Ltd · NCT06824155Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer
Phase N/A · 1 location(s) · Blokhin's Russian Cancer Research Center · NCT06449989Elacestrant in Advanced Triple Positive Breast Cancer
Phase 1/Phase 2 · 1 location(s) · NYU Langone Health · NCT07612215Disitamab Vedotin in Combination with Tislelizumab and Bevacizumab in a Phase II Clinical Study of Locally Advanced or M
Phase 2 · 1 location(s) · Shanghai Pulmonary Hospital, Shanghai, China · NCT06749860PD-1 Combined With Pyrotinib for Chemotherapy Failure HER2 Insertion Mutation Advanced NSCLC
Phase 2 · 1 location(s) · Yongchang Zhang · NCT04144569Integrated Testing Strategy for Simultaneous Detection of ESR-1 and gBRCA Mutations Via Liquid Biopsy in HR+/HER2- Metas
Phase N/A · 1 location(s) · European Institute of Oncology · NCT06762483Evexomostat Plus PI3K or AKT Inhibitor and Fulvestrant in Patients With a PI3K Alteration and HR+/Her2- Breast Cancer
Phase 1/Phase 2 · 10 location(s) · SynDevRx, Inc. · NCT05455619Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomark
NA · 25 location(s) · Institut Claudius Regaud · NCT05378204DESTINY-PANTUMOUR04
Phase N/A · 18 location(s) · AstraZeneca · NCT07124000SHARON: A Clinical Trial for Metastatic Cancer Using Chemotherapy and Patients' Own Stem Cells
Phase 1 · 2 location(s) · General Oncology, Inc. · NCT04150042First in Human Study of BAY2927088 in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations i
Phase 1/Phase 2 · 94 location(s) · Bayer · NCT05099172A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Phase 2 · 10 location(s) · Memorial Sloan Kettering Cancer Center · NCT06123338Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i.
Phase 3 · 99 location(s) · MedSIR · NCT06382948PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)
Phase 2 · 1 location(s) · Kristina A. Fanucci · NCT07222215Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC
Phase 1 · 1 location(s) · H. Lee Moffitt Cancer Center and Research Institute · NCT05681780First-in-Human Study of Tersolisib (STX-478) as Monotherapy and in Combination With Other Antineoplastic Agents in Parti
Phase 1/Phase 2 · 65 location(s) · Eli Lilly and Company · NCT05768139Fluzoparib Combined With Camrelizumab for Neoadjuvant Treatment of Embryogenic BRCA Mutation HER2 Negative Breast Cancer
Phase 2 · 1 location(s) · Peking University People's Hospital · NCT05576389A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus R
Phase 2 · 49 location(s) · Hoffmann-La Roche · NCT07405801A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Particip
Phase 3 · 352 location(s) · Hoffmann-La Roche · NCT06065748First-In-Human Study of STX-721/PFL-721 in Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer H
Phase 1/Phase 2 · 24 location(s) · Pierre Fabre Medicament · NCT06043817
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.